Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Oncology · Graft-Versus-Host Disease

The Biology of GVHD: Why and How It Happens

At a Glance

Graft-Versus-Host Disease (GVHD) occurs when a newly transplanted immune system mistakenly attacks the recipient's healthy tissues. It can present as rapid inflammation (acute) or long-term autoimmune scarring (chronic), often influenced by gut bacteria health and prior tissue damage.

Understanding the biology of Graft-Versus-Host Disease (GVHD) helps demystify why your body is reacting this way. At its core, GVHD is a case of “mistaken identity” where your new immune system is being a bit too overprotective.

The Biological “Attack”

To understand GVHD, imagine your new donor immune system as a security team. This team’s primary job is to find and eliminate threats like cancer cells or infections. However, during a transplant, the “host” (your body) can experience some tissue stress from the chemotherapy or radiation used to prepare you for the graft [1].

When your cells are stressed or damaged, they can release “danger signals,” including fragments of DNA [2]. A specific biological alarm system called the STING pathway (Stimulator of Interferon Genes) detects this loose DNA and sounds the alert [2]. Your new donor T cells—the “soldiers” of the immune system—hear this alarm and may mistakenly identify your healthy organs as the enemy, leading to an immune attack [3][2].

Acute vs. Chronic: Timing and Behavior

While they share a name, acute and chronic GVHD behave quite differently in the body.

1. Acute GVHD (aGVHD)

  • Mechanism: This is a rapid, inflammatory response [4]. Think of it like a “flash fire” where the immune system causes sudden, sharp inflammation, primarily in the skin, liver, or gut [5].
  • Timing: Traditionally occurs within the first 100 days after transplant [6].
  • Late-Onset Acute GVHD: Sometimes, these “flash fire” symptoms don’t appear until after day 100 [7]. Biologically, this is still acute GVHD—it just has a delayed start, often because the medications used to suppress the immune system were tapered or changed [4][8].

2. Chronic GVHD (cGVHD)

  • Mechanism: This is more like a “slow simmer.” It behaves less like sudden inflammation and more like an autoimmune disorder (where the body attacks itself over a long period) [9]. It involves a complex mix of immune cells, including B cells, which can lead to scarring or “fibrosis” in tissues like the skin, lungs, or joints [10][11].
  • Timing: Usually develops later, often months or even years after transplant [5].

3. Overlap Syndrome

In some cases, a patient may experience Overlap Syndrome, where features of both acute and chronic GVHD are present at the same time [12]. This requires careful management because the body is dealing with both sudden inflammation and long-term autoimmune-like changes simultaneously [13].

The Role of the Gut “Microbiome”

Recent science has highlighted the importance of your microbiota—the trillions of “good” bacteria living in your gut. When these bacteria are healthy and diverse, they produce “messages” (metabolites) that help keep the immune system calm [14][15].

However, the transplant process can cause dysbiosis, which is an imbalance where the diversity of these good bacteria is lost [16]. When the gut is in dysbiosis, it can no longer send those “calm down” signals to the new immune system, which may make GVHD more likely or more severe [16][17]. Keeping your gut healthy is now recognized as a vital part of managing GVHD [18].

Feature Acute GVHD Chronic GVHD
Primary Cells T cells (Inflammatory) T cells & B cells (Autoimmune)
Typical Organs Skin, Liver, GI Tract Eyes, Mouth, Skin, Lungs, Joints
Feeling Sudden, “Angry” inflammation Slow, “Scarring” or dryness
Timing Often < 100 days Often > 100 days

Common questions in this guide

What is the difference between acute and chronic GVHD?
Acute GVHD is a rapid, inflammatory response that typically occurs within the first 100 days after a transplant. Chronic GVHD develops more slowly, often months or years later, and behaves more like an autoimmune disorder that causes tissue scarring.
Can acute GVHD happen after 100 days?
Yes. This is called late-onset acute GVHD. It happens when sudden, inflammatory symptoms of acute GVHD appear after the traditional 100-day mark, often triggered by changes in your immune-suppressing medications.
What is GVHD overlap syndrome?
Overlap syndrome occurs when a patient has features of both acute and chronic GVHD at the same time. This means your body is dealing with sudden inflammation and long-term autoimmune changes simultaneously.
How does my gut health affect GVHD?
A healthy gut microbiome produces signals that help keep your new immune system calm. If the transplant process causes an imbalance in these beneficial gut bacteria, known as dysbiosis, it can increase the risk or severity of GVHD.
Why does my new immune system attack my body?
During a transplant, tissue damage from chemotherapy or radiation releases danger signals like DNA fragments. Your new donor T cells detect these signals and mistakenly identify your healthy organs as a threat, triggering an immune attack.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my symptoms and the timing of my transplant, do I have classic acute GVHD, late-onset acute GVHD, or chronic GVHD?
  2. 2.Do my current symptoms indicate 'overlap syndrome,' and how does that change the treatment approach?
  3. 3.Is there evidence of gut dysbiosis in my case, and are there specific dietary changes or supplements you recommend to support my microbiome?
  4. 4.Are we monitoring any specific biological markers, such as ST2 or REG3α, to track the activity of my GVHD?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Deciphering the role of the major histocompatibility complex, the intestinal microbiome and metabolites in the pathogenesis of acute graft-versus-host disease.

    Wenger V, Zeiser R

    Best practice & research. Clinical haematology 2024; (37(3)):101567 doi:10.1016/j.beha.2024.101567.

    PMID: 39396261
  2. 2

    STING and transplantation: can targeting this pathway improve outcomes?

    Bader CS, Jin L, Levy RB

    Blood 2021; (137(14)):1871-1878 doi:10.1182/blood.2020008911.

    PMID: 33619537
  3. 3

    Acute graft-vs-host disease, pathophysiology, prevention, and treatment: Something old and something new.

    Cohan N, Ramzi M, Dermarderosian A, Akhtari M

    Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2026; (74(1)):3-15 doi:10.1177/10815589251359314.

    PMID: 40621931
  4. 4

    Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

    Holtan SG, Khera N, Levine JE, et al.

    Blood 2016; (128(19)):2350-2358 doi:10.1182/blood-2015-09-669846.

    PMID: 27625357
  5. 5

    Diagnostic and prognostic role of elafin in skin acute graft versus host disease: a systematic review.

    Bhattarai A, Shah S, Yadav R, et al.

    Hematology (Amsterdam, Netherlands) 2024; (29(1)):2293497 doi:10.1080/16078454.2023.2293497.

    PMID: 38112182
  6. 6

    Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

    Zeiser R, Blazar BR

    The New England journal of medicine 2017; (377(22)):2167-2179 doi:10.1056/NEJMra1609337.

    PMID: 29171820
  7. 7

    Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD.

    Akahoshi Y, Spyrou N, Hogan WJ, et al.

    Blood advances 2023; (7(16)):4479-4491 doi:10.1182/bloodadvances.2023009885.

    PMID: 37315175
  8. 8

    Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.

    Cuvelier GDE, Nemecek ER, Wahlstrom JT, et al.

    Blood 2019; (134(3)):304-316 doi:10.1182/blood.2019000216.

    PMID: 31043425
  9. 9

    Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD.

    Mirgh S, Gokarn A, Punatar S, et al.

    Transplant infectious disease : an official journal of the Transplantation Society 2021; (23(4)):e13576 doi:10.1111/tid.13576.

    PMID: 33523551
  10. 10

    Complex interactions of cellular players in chronic Graft-versus-Host Disease.

    Gail LM, Schell KJ, Łacina P, et al.

    Frontiers in immunology 2023; (14()):1199422 doi:10.3389/fimmu.2023.1199422.

    PMID: 37435079
  11. 11

    Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.

    Chen X, Wang Y, Huang X, et al.

    International immunopharmacology 2023; (117()):109746 doi:10.1016/j.intimp.2023.109746.

    PMID: 36827923
  12. 12

    Quality of Life in the Chronic GVHD Consortium Cohort: Lessons Learned and the Long Road Ahead.

    Krupski C, Jagasia M

    Current hematologic malignancy reports 2015; (10(3)):183-91 doi:10.1007/s11899-015-0265-2.

    PMID: 26303672
  13. 13

    Classification systems for chronic graft-versus-host disease.

    Lee SJ

    Blood 2017; (129(1)):30-37 doi:10.1182/blood-2016-07-686642.

    PMID: 27821503
  14. 14

    Pre-Administration of Akkermansia Muciniphila Prevents the Development of Severe Acute Graft-Versus-Host Disease in Systemic Organs.

    Han JE, Lee DS, Jeong SW, et al.

    Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026; (13(9)):e15982 doi:10.1002/advs.202415982.

    PMID: 41319282
  15. 15

    A Promising Insight: The Potential Influence and Therapeutic Value of the Gut Microbiota in GI GVHD.

    Li J, Zhang X, Chen Y, et al.

    Oxidative medicine and cellular longevity 2022; (2022()):2124627 doi:10.1155/2022/2124627.

    PMID: 35571252
  16. 16

    Allogenic stem cell transplant-associated acute graft versus host disease: a computational drug discovery text mining approach using oral and gut microbiome signatures.

    Beckman MF, Morton DS, Bahrani Mougeot F, Mougeot JC

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2021; (29(4)):1765-1779 doi:10.1007/s00520-020-05821-2.

    PMID: 33094358
  17. 17

    Gut microbiota and acute graft-versus-host disease.

    Yoshioka K, Kakihana K, Doki N, Ohashi K

    Pharmacological research 2017; (122()):90-95 doi:10.1016/j.phrs.2017.05.028.

    PMID: 28576475
  18. 18

    The gut microbiota in transplant patients.

    Chong PP, Koh AY

    Blood reviews 2020; (39()):100614 doi:10.1016/j.blre.2019.100614.

    PMID: 31492463

This page explains the biological mechanisms of Graft-Versus-Host Disease for educational purposes only. Always consult your transplant team or oncologist for personalized medical advice regarding your GVHD symptoms.

Get notified when new evidence is published on Graft versus host disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.